Full Text
Budget Impact of a Fixed-Dose Combination Therapy of Lesinurad and Allopurinol for Second-Line Gout Therapy- A US Commercial Health Plan Perspective

Abstract

Authors

A Fu D Taylor

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×